酪氨酸激酶抑制剂治疗Ph＋急性淋巴细胞白血病的研究进展  

Research Progress of Tyrosine Kinase Inhibitors in Treatment of Patients with Ph＋ Acute Lymphoblastic Leukemia

作　　者：马莎[1] 陈翀[1] 徐开林[1] 

机构地区：[1]徐州医学院移植免疫重点实验室徐州医学院附属医院血液科,221000

出　　处：《国际输血及血液学杂志》2014年第6期547-550,共4页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金项目（81000210,81272206）

摘　　要：在急性淋巴细胞白血病（ALL）患者中,约20％成年及50％老年患者表达Ph,统称为Ph＋ ALL.与Ph ALL相比,Ph＋ ALL的完全缓解率（CR）低、预后极差.近年,应用酪氨酸激酶抑制剂（TKI）治疗Ph＋ ALL,可明显提高患者的缓解率,然而复发率仍然很高.目前,异基因造血干细胞移植是治愈CR1期Ph＋ ALL患者的最佳手段.Ph＋ ALL的进一步的治疗策略包括移植后TKI的应用及新一代TKI的研发.Among acute lymphoblastic leukemia （ALL） patients,approximately 20％ adult and 50％ elderly patients express Ph,known as Ph＋ ALL.Ph＋ ALL has a lower complete remission （CR） rate than that of Ph-negative （Ph-） ALL and with an extremely poor prognosis overall.The use of tyrosine kinase inhibitors （TKI） has resulted in higher rate of CR,but the relapse rate is still very high.Currently,allogeneic hematopoietic stem cell transplantation is the best treatment program for Ph＋ ALL patients in CR1.Further strategies have also included incorporation of TKI in the post-transplant and the use of the newer generation TKI.

关 键 词：费城染色体 淋巴细胞白血病 急性 造血干细胞移植 酪氨酸激酶抑制剂 

分 类 号：R733.71[医药卫生—肿瘤]